|1.||Hashimoto, Kenji: 2 articles (05/2009 - 01/2008)|
|2.||Iyo, Masaomi: 2 articles (05/2009 - 01/2008)|
|3.||Ishiwata, Kiichi: 1 article (05/2009)|
|4.||Ishikawa, Masatomo: 1 article (05/2009)|
|5.||Wu, Jin: 1 article (05/2009)|
|6.||Ishii, Kenji: 1 article (05/2009)|
|7.||Oda, Keiichi: 1 article (05/2009)|
|8.||Sakata, Muneyuki: 1 article (05/2009)|
|9.||Toyohara, Jun: 1 article (05/2009)|
|10.||Takahagi, Makoto: 1 article (01/2008)|
|1.||Schizophrenia (Dementia Praecox)
01/01/2008 - "The present findings suggest that [11C]CHIBA-1001 could be a novel useful PET ligand for in vivo study of the receptor occupancy and pathophysiology of alpha7 nAChRs in the intact brain of patients with neuropsychiatric diseases such as schizophrenia and Alzheimer's disease."
01/01/2008 - "Interestingly, the binding of [11C]CHIBA-1001 in the frontal cortex of the monkey brain was significantly decreased by subchronic administration of the N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (0.3 mg/kg, twice a day for 13 days); which is a non-human primate model of schizophrenia. "
|2.||Alzheimer Disease (Alzheimer's Disease)
|3.||Body Weight (Weight, Body)
|3.||Phencyclidine (Angel Dust)